- Home
- SGA vs PLRX Comparison
SGA vs PLRX Comparison
Compare SGA & PLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SGA | PLRX |
|---|---|---|
| Founded | 1986 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Broadcasting | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 73.7M | 79.9M |
| IPO Year | 1994 | 2020 |
Fundamental Metrics
Financial Performance| Metric | SGA | PLRX |
|---|---|---|
| Price | $11.12 | $1.28 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $2.67 |
| AVG Volume (30 Days) | 8.4K | ★ 615.4K |
| Earning Date | 03-12-2026 | 03-11-2026 |
| Dividend Yield | ★ 8.94% | N/A |
| EPS Growth | N/A | ★ 29.97 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $124,829,000.00 | N/A |
| Revenue This Year | $6.74 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 5.65 | N/A |
| 52 Week Low | $10.68 | $1.09 |
| 52 Week High | $14.27 | $1.95 |
Technical Indicators
Market Signals| Indicator | SGA | PLRX |
|---|---|---|
| Relative Strength Index (RSI) | 42.76 | 50.82 |
| Support Level | $10.68 | $1.12 |
| Resistance Level | $12.60 | $1.36 |
| Average True Range (ATR) | 0.22 | 0.07 |
| MACD | -0.05 | 0.00 |
| Stochastic Oscillator | 23.63 | 31.71 |
Price Performance
Historical ComparisonAbout SGA Saga Communications Inc. (FL)
Saga Communications Inc is a broadcast company engaged in acquiring, developing, and operating broadcast properties. The company's objective is to operate top billing radio stations in mid-sized markets. It derives a majority of its revenue from the sale of advertising for broadcast on its stations.
About PLRX Pliant Therapeutics Inc.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.